PTK6: Protein-tyrosine kinase 6
Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PTK6, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| VandetanibBoxed warning | Approved | Sanofi | Small molecule | InhibitorTyrosine-protein kinase BRK inhibitor | 3 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | Vandetanib | Phase 2 | Recruiting | West China Hospital | Jul 1, 2024 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | Vandetanib | Phase 3 | Active, not recruiting | Loxo Oncology, Inc. | Dec 26, 2019 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | Vandetanib | Phase 2 | Active, not recruiting | UNICANCER | Nov 24, 2014 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Medullary thyroid gland carcinoma
- 0.59
- Non-small cell lung carcinoma
- 0.46
- Thyroid gland carcinoma
- 0.44
- Neoplasm
- 0.40
- Colorectal adenocarcinoma
- 0.38
- Skin basal cell carcinoma
- 0.37
- Thyroid tumor
- 0.37
- Endometrial endometrioid adenocarcinoma
- 0.37
- Gastric carcinoma
- 0.37
- Breast carcinoma
- 0.31
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4601, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q13882, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets